Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study

The long-term outcome of first-line moderate-intensity statin with ezetimibe combination therapy for secondary prevention after percutaneous coronary intervention in patients with acute coronary syndrome (ACS) compared to high-intensity statin monotherapy remains elusive. The objective of this study...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-01, Vol.14 (1), p.838-838, Article 838
Main Authors: Jang, Ji-Yong, Kim, Seonji, Cho, Jaehyeong, Chun, Sung-youn, You, Seng Chan, Kim, Jung-Sun
Format: Article
Language:English
Subjects:
692/308
692/4019
692/699
692/700
Acute Coronary Syndrome - drug therapy
Acute coronary syndromes
Cardiovascular diseases
Cerebral infarction
Cohort analysis
Cohort Studies
Ezetimibe - therapeutic use
Humanities and Social Sciences
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male
multidisciplinary
Myocardial infarction
Population studies
Retrospective Studies
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The long-term outcome of first-line moderate-intensity statin with ezetimibe combination therapy for secondary prevention after percutaneous coronary intervention in patients with acute coronary syndrome (ACS) compared to high-intensity statin monotherapy remains elusive. The objective of this study was to compare the effectiveness of moderate-intensity statin and ezetimibe combination therapy with high-intensity statin monotherapy. We conducted a nationwide, population-based, retrospective, cohort study of patients with ACS from 2013 to 2019. The patients using combination therapy were matched (1:1) to those using monotherapy. The primary outcome was a composite of myocardial infarction, stroke and all-cause mortality. We estimated the hazard ratios (HR) and 95% confidence intervals (CIs) using the Cox proportional hazards regression. After propensity score matching, 10,723 pairs were selected. Men accounted for 70% of the patients and 37% aged > 70 years. The primary endpoint occurred in 1297 patients (12.1%) in the combination group and in 1426 patients (13.3%) in the monotherapy group, and decreased risk (HR 0.85, 95% CI 0.78–0.92, P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-51310-5